Kremezin (AST-120) is a commonly used oral adsorbent that supports the management of symptoms linked to organ-specific functional stress, specifically in the context of chronic kidney disease (CKD). This therapy is considered relevant in conditions characterized by periods of heightened symptoms and is commonly applied across therapeutic domains where additional symptomatic support is needed, assisting with the management of the systemic burden caused by the presence of certain substances.

This treatment is considered relevant in conditions where functional stability becomes affected and is commonly used for the improvement of uremic symptoms in patients with CKD. The treatment may help patients cope more steadily with symptom fluctuations, thereby contributing to improved comfort during symptomatic periods. The overall benefit is focused on providing support that helps ease the overall symptom burden. Clinically, it is applied in scenarios involving the management of symptoms related to uremia and chronic kidney disease. The treatment supports general well-being during symptomatic phases and is relevant in contexts involving heightened systemic burden.

---

Symptom Support Focus: Uremic Symptoms

Eligibility for Kremezin (AST-120): Official Regulatory Status

The eligibility for Kremezin is strictly defined by regulatory documentation from various national health authorities.

Population Status	Official Regulatory Rule
Allowed Population	Established for adult patients with Chronic Kidney Disease (CKD).
Age Restriction	Use is not established or recommended for the pediatric population (under 18 years of age).
Pregnancy Status	Officially Contraindicated / Prohibited in pregnant women.

---

Contraindications and Restricted Use

Use of Kremezin is contraindicated in patients with a known hypersensitivity to AST-120. Eligibility is also prohibited for patients with certain pre-existing gastrointestinal conditions, reflecting the drug’s non-systemic nature. These restrictions include: severe constipation (requiring daily laxative use) and a recent history of peptic ulcers (typically within the last month). Use is also restricted by specific thresholds of abnormal liver function and in high-vulnerability populations, such as patients with cancer or hematological malignancies.

Official Pharmacokinetic Interaction Profile

The entire regulatory interaction profile for Kremezin (Ast-120) is defined by its core action as a non-systemic intestinal adsorbent. This function leads to a single, high-level pharmacokinetic interaction pattern: the physical binding and subsequent reduction in the systemic exposure of other oral medicinal products.

Interaction Type	Specific Documentation Findings
Exposure-Modifying Effect	Co-administration leads to a documented reduction in Area Under the Curve (AUC) and maximum plasma concentration (C max) of certain oral drugs.
Specific Interacting Agents	Amlodipine, Triazolam, Metoprolol Extended Release, and Aspirin (in combination products) are specifically cited in regulatory studies for showing decreased exposure with simultaneous administration.
Metabolic/Transporter Risk	None documented. The drug's non-systemic nature precludes involvement in CYP-mediated or transporter-based interactions, such as P-gp.

Interaction-Related Constraint

To mitigate the documented adsorption risk, regulatory guidance includes a Mandatory Administration Timing Separation. Other oral medicinal products must be administered at least 30 to 90 minutes prior to the administration of Kremezin. This constraint is required to ensure sufficient absorption of concomitant oral drugs and is the primary management strategy for this clinically significant interaction. No contraindicated combinations or population-specific interaction considerations are formally stated in the labels.

The mechanism of Kremezin (Ast-120) is defined by its function as a non-absorbable Spherical Carbon Adsorbent, operating entirely through a physical sequestration process within the gastrointestinal tract. The mechanism does not involve direct interaction with human receptors or enzymes.

Gastrointestinal Toxin Precursor Clearance

This domain covers the primary molecular target and interaction type: the physical binding of small, non-polar molecules like indole (a precursor of Indoxyl Sulfate, IS) and p-cresol in the colon. By trapping these microbial metabolites and facilitating their excretion via the stool, the drug performs a gut clearance function, preventing their systemic absorption.

Attenuation of Systemic Pathological Signaling

This domain describes the resulting physiological cascade: the successful reduction of absorbed precursors leads to a lower plasma concentration of toxic compounds like Indoxyl Sulfate. This lowered systemic burden indirectly modulates harmful pathways by reducing the pathological activation of the Aryl Hydrocarbon Receptor (AhR) in tissues. This helps limit the resulting pro-inflammatory and oxidative stress signaling, which contributes to the mitigation of cellular damage in the vasculature and kidneys.

Mechanism Constraints and Non-Specificity

This domain addresses the inherent limitations of the physical mechanism: the non-selectivity of adsorption means the drug has the potential to bind other small organic molecules co-administered orally. Furthermore, because Ast-120 is non-absorbable, its action is restricted to the gut lumen and has negligible direct effect on the uremic toxins already protein-bound and circulating in the blood.

How Kremezin is Used: Official Administration Guidelines

Kremezin (Ast-120) is an oral adsorbent used for the continuous management of chronic conditions, with administration instructions standardized for its approved use. The official usage pattern is defined by a fixed daily dose taken in multiple administrations.

---

Standard Labeled Dosing Regimen

The most commonly cited standard adult daily dose is 6 grams of the active ingredient (Spherical Carbon Adsorbent). This total amount is split into separate administrations to be taken throughout the day.

• Route: Oral administration.
• Frequency: Three times a day (TID).
• Dose Per Administration: The total daily dose is typically divided into three doses of 2 grams each.
• Duration: The medicine is intended for long-term, continuous therapy to support the ongoing management of chronic kidney disease.

---

Administration Conditions and Handling

The proper administration of Kremezin focuses heavily on timing, which is a procedural requirement tied to its function as an adsorbent.

• Timing: The doses are typically instructed to be taken between meals. This timing helps ensure the compound is available in the gastrointestinal tract without directly interfering with food absorption. Clinical trial protocols have also utilized administration with meals.
• Separation from Other Medicines: Due to its binding capacity, Kremezin must not be taken at the same time as other oral medicines. Official instructions recommend waiting more than 30 minutes to 1 hour after taking other medicines before administering Kremezin.
• Preparation: Granules or tablets should be taken with a sufficient amount of water.
• Missed Doses: If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose. Two doses must never be taken at one time to make up for a missed dose.
• Population Adjustments: No specific, uniform dose adjustment for older adults is mandated in the official prescribing information, suggesting the standard 6-gram regimen applies broadly across the adult population.

Kremezin: Recent Clinical Evidence

Evidence for Use in Managing Uremic Symptoms in CKD

Research has extensively examined Kremezin’s effect in adult patients diagnosed with Chronic Kidney Disease (CKD) experiencing periods of heightened symptom activity associated with uremia. These studies monitored outcomes related to physical discomfort and patient-reported experiences, often using randomized controlled trials (RCTs). Trials reported that, in some groups, patients reported changes in uremic symptoms, such as observed patterns in the measurement of uremic pruritus (itching) intensity. However, the overall evidence suggests that the extent of the change was observed in some studies but was not uniform across all observed populations.

---

Evidence Related to Toxin Burden Reduction and Renal Progression Markers

Clinical research explored whether Kremezin affects the body's systemic balance by focusing on toxin burden and renal disease progression markers. Studies consistently monitored the levels of specific uremic toxins (like indoxyl sulfate), showing patterns related to a measured shift in their concentration. At the same time, the research examined markers of kidney function itself (e.g., eGFR decline). The largest multinational trials reported that the most common composite renal endpoint was not significantly different in the overall CKD population studied. Findings regarding the slowing of kidney function decline were generally mixed.

---

Research Gaps and Uncertainties

The evidence quality varies across studies, and limitations remain. Although some extended trials provided observation periods of up to two to four years, long-term effects are not fully established, and certainty remains low for multi-decade prognosis. Furthermore, data for special groups like pediatric populations are insufficient or limited. Subgroup findings, which sometimes described patterns in the rate of decline, are uncertain as they often rely on analyses conducted after the initial study results were known. Research is ongoing to provide clearer insights.

Key Studies & References

1. Efficacy of AST-120 for Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials
2. AST-120 improved uremic pruritus by lowering indoxyl sulfate and inflammatory cytokines in hemodialysis patients

Common questions about Kremezin (FAQ)

---

Q: Is Kremezin available over the counter?

A: Kremezin is classified as a prescription-only oral medication in the countries where it is approved. This means the drug requires authorization from a healthcare professional to be obtained.

---

Q: How is Kremezin classified by the FDA or other regulatory bodies?

A: Official regulatory agencies classify Kremezin as a Non-systemic Intestinal Adsorbent and a Uremic Toxin Adsorbent. This classification reflects that it acts only in the gut and is intended to help reduce the burden of certain waste products associated with kidney conditions.

---

Q: What is the role of Kremezin in managing chronic kidney disease (CKD)?

A: Its regulatory indication is defined as helping to alleviate uremic symptoms and/or prolonging the time to the initiation of dialysis in patients with progressive Chronic Kidney Disease (CKD).

---

Q: Is Kremezin used in people without severe kidney problems?

A: The regulatory indication for the drug is strictly established for use in adult patients with Chronic Kidney Disease (CKD). Official information does not support its use outside of this specific patient population.

---

Q: Is Kremezin a type of dialysis treatment?

A: No, Kremezin is not a form of dialysis. It is classified as an oral adsorbent that works in the gut to reduce toxin load. The drug is actually indicated to delay the need for dialysis in certain patients, distinguishing it from the treatment itself.

---

Q: Why is Kremezin sometimes mentioned in discussions about gut health?

A: The medicine's mechanism is defined by its non-absorbable nature and its action that takes place solely within the gastrointestinal tract. It performs a gut clearance function by physically trapping and removing specific microbial metabolites before they can be absorbed into the bloodstream.

---

Q: What is the difference between Kremezin and charcoal supplements?

A: Official documents describe Kremezin's active ingredient as a synthetic compound made of specialized, highly porous carbon microspheres. The official description notes that this composition is different from general activated charcoal.

---

Q: Is Kremezin the same as other toxin binders?

A: The official product description highlights its unique structure as an oral Spherical Carbon Adsorbent, differentiating it from other types of binders.

---

Q: How long does it typically take for Kremezin to start having an effect?

A: Clinical studies focusing on the drug's action have noted patterns related to the reduction in uremic toxin levels (such as indoxyl sulfate) as early as 4 weeks into treatment.

---

Q: What evidence supports the use of Kremezin?

A: Evidence themes include patterns related to the reduction of uremic toxin levels and observations regarding kidney function markers (like eGFR decline) in certain patient groups, though overall trial results have been mixed.

---

Q: Is Kremezin linked to any serious but rare side effects?

A: Official safety documentation notes adverse events are generally mild to moderate. However, severe constipation is specifically noted as a potential safety issue that has led to treatment discontinuation in some patients.

---

Q: Is Kremezin suitable for people with a history of digestive blockages?

A: Official regulatory documents advise against the use of this drug in patients with pre-existing conditions like severe constipation or certain transit disorders in the digestive tract, such as intestinal obstruction. This restriction is due to the drug's physical, non-systemic mechanism of action within the digestive tract.

---

Q: Can Kremezin affect the absorption of certain vitamins or minerals?

A: Official information indicates the drug has the potential to bind to and reduce the systemic exposure of certain other oral medicinal products if taken too closely together. Due to the non-selective nature of this physical binding mechanism, official information states there is potential for it to also affect the absorption of other small molecules, which could include vitamins or minerals.

---

Q: Are there specific food items that must be avoided while taking Kremezin?

A: Official instructions specify that the dose is typically taken between meals. This timing is designed to minimize any potential interference with general food absorption, though official documents do not list specific food items that must be entirely avoided.

---

Q: Can Kremezin be crushed or opened if swallowing is difficult?

A: Regulatory instructions define the product as granules to be taken with water. Official regulatory text does not provide instructions for opening the capsule or crushing the granules, suggesting the physical integrity is important for proper function.

---

Q: Is it possible for Kremezin to change the color of stool?

A: Yes, due to the physical nature of the active ingredient, which is a carbon adsorbent, a darkening of the stool color is an expected and commonly described physical effect of taking the medicine.

---

Q: Does Kremezin affect lab test results for blood or urine?

A: While the drug reduces blood levels of specific uremic toxins, clinical data for its use in CKD patients has generally noted no significant differences in the levels of common routine lab markers like BUN, serum creatinine, and eGFR.

How to Store and Dispose of Kremezin (Adsorbed Carbon)

Kremezin capsules must be stored within a specific range defined as Controlled Room Temperature (CRT), which is 20 C to 25 C (68 F to 77 F). Temperature excursions between 15 C and 30 C (59 F and 86 F) are permitted.

Required Storage and Protection

Storage Requirement	Rule
Temperature	Controlled Room Temperature (20 C-25 C)
Container	Store in the original container and keep the bottle tightly closed.
Environment	Must be protected from moisture to maintain product stability.
Child Safety	Keep the medicine out of the reach of children.

Disposal of any expired or unused Kremezin must be handled according to local regulations. Medicine should not be thrown into household trash or poured down a drain unless explicitly authorized by a local regulatory body.